OTCMKTS:PPCB Propanc Biopharma (PPCB) Stock Price, News & Analysis $5.50 +0.25 (+4.76%) As of 03/31/2025 03:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsSEC FilingsShort InterestBuy This Stock About Propanc Biopharma Stock (OTCMKTS:PPCB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Propanc Biopharma alerts:Sign Up Key Stats Today's Range$5.00▼$5.5850-Day Range$0.00▼$25.0052-Week Range$2.76▼$222.00Volume2,203 shsAverage Volume427 shsMarket Capitalization$104,500.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPropanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.Read More… Remove Ads Receive PPCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address PPCB Stock News HeadlinesPropanc Biopharma Inc (PPCB)August 21, 2024 | investing.comPropanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North AmericaAugust 14, 2024 | finance.yahoo.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 1, 2025 | Paradigm Press (Ad)VTXB Vortex Brands Co.May 29, 2024 | seekingalpha.comPropanc Biopharma, Inc. (PPCB)May 29, 2024 | finance.yahoo.comPropanc Biopharma Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent OfficeApril 16, 2024 | finance.yahoo.comPropanc Biopharma's CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic FinancingApril 10, 2024 | stockhouse.comPropanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic FinancingApril 8, 2024 | finance.yahoo.comSee More Headlines PPCB Stock Analysis - Frequently Asked Questions How have PPCB shares performed this year? Propanc Biopharma's stock was trading at $0.0002 at the start of the year. Since then, PPCB shares have increased by 2,749,900.0% and is now trading at $5.50. View the best growth stocks for 2025 here. When did Propanc Biopharma's stock split? Shares of Propanc Biopharma reverse split on the morning of Tuesday, May 23rd 2023. The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How do I buy shares of Propanc Biopharma? Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Propanc Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Propanc Biopharma investors own include T2 Biosystems (TTOO), AppYea (APYP), Avis Budget Group (CAR), PayPal (PYPL), Synthetic Biologics (SYN), Corbus Pharmaceuticals (CRBP) and Delcath Systems (DCTH). Company Calendar Today4/01/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:PPCB CIK1517681 Webwww.propanc.com Phone(139) 882-0780Fax61 03 9882 9969Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,820,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-1,756.61% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-550.00Miscellaneous Outstanding Shares19,000Free Float869,584,000Market Cap$104,500.00 OptionableNot Optionable Beta1.84 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:PPCB) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Propanc Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Propanc Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.